Prospective placebo‐controlled randomized trial of lexipafant in predicted severe acute pancreatitis

Background Many patients with severe acute pancreatitis develop organ system failure during the first few days of illness, and this accounts for the majority of early deaths. No specific therapy is available and treatment remains supportive.

[1]  C. McKay,et al.  A randomized, controlled trial of octreotide in the management of patients with acute pancreatitis , 1997, International journal of pancreatology : official journal of the International Association of Pancreatology.

[2]  L. Czakó,et al.  Time-course changes in serum cytokine levels in two experimental acute pancreatitis models in rats , 1996, Research in experimental medicine. Zeitschrift fur die gesamte experimentelle Medizin einschliesslich experimenteller Chirurgie.

[3]  K. Fearon,et al.  Proinflammatory cytokine release by peripheral blood mononuclear cells from patients with acute pancreatitis , 1996, The British journal of surgery.

[4]  C. McKay,et al.  Increased monocyte cytokine production in association with systemic complications in acute pancreatitis , 1996, The British journal of surgery.

[5]  M. Kotb,et al.  Anti-TNFalpha therapy improves survival and ameliorates the pathophysiologic sequelae in acute pancreatitis in the rat. , 1996, American journal of surgery.

[6]  M. Kotb,et al.  Up-regulation of TNFα mRNA in the rat spleen following induction of acute pancreatitis , 1995 .

[7]  L. Formela,et al.  Randomized, double‐blind phase II trial of Lexipafant, a platelet‐activating factor antagonist, in human acute pancreatitis , 1995, The British journal of surgery.

[8]  L. Wood,et al.  Amelioration of experimental acute pancreatitis with a potent platelet‐activating factor antagonist , 1994, The British journal of surgery.

[9]  G. Camussi,et al.  Role of platelet activating factor in acute pancreatitis induced by lipopolysaccharides in rabbits. , 1994, European journal of pharmacology.

[10]  H. Reber,et al.  Clinically based classification system for acute pancreatitis. , 1993, Pancreas.

[11]  E L Bradley,et al.  A clinically based classification system for acute pancreatitis. Summary of the International Symposium on Acute Pancreatitis, Atlanta, Ga, September 11 through 13, 1992. , 1993, Archives of surgery.

[12]  P. Malfertheiner,et al.  Gabexate mesilate in human acute pancreatitis , 1993 .

[13]  A. Shenkin,et al.  Role of interleukin-6 in mediating the acute phase protein response and potential as an early means of severity assessment in acute pancreatitis. , 1993, Gut.

[14]  J. Stachura,et al.  Role of platelet activating factor in pathogenesis of acute pancreatitis in rats. , 1992, Gut.

[15]  F. Carballo,et al.  Role of interleukin-6 in acute pancreatitis. Comparison with C-reactive protein and phospholipase A. , 1992, Gut.

[16]  J. Schölmerich,et al.  lnterleukin‐8 and neutrophil activation in acute pancreatitis , 1992, European journal of clinical investigation.

[17]  C. Scheibenbogen,et al.  Elevation of serum interleukin-6 concentration precedes acute-phase response and reflects severity in acute pancreatitis. , 1991, Gastroenterology.

[18]  C. Imrie,et al.  Prediction of outcome in acute pancreatitis: A comparative study of APACHE II, clinical assessment and multiple factor scoring systems , 1990, The British journal of surgery.

[19]  D. Hosford,et al.  PAF/cytokine auto-generated feedback networks in microvascular immune injury: consequences in shock, ischemia and graft rejection. , 1989, Journal of lipid mediators.

[20]  W. Hsueh,et al.  Bowel necrosis induced by tumor necrosis factor in rats is mediated by platelet-activating factor. , 1988, The Journal of clinical investigation.

[21]  P. Bell,et al.  Multicentre clinical trial of low volume fresh frozen plasma therapy in acute pancreatitis , 1987, The British journal of surgery.

[22]  R. Williamson,et al.  Controlled clinical trial of peritoneal lavage for the treatment of severe acute pancreatitis. , 1985, The New England journal of medicine.

[23]  M. Young,et al.  Sample size nomograms for interpreting negative clinical studies. , 1983, Annals of internal medicine.

[24]  J. C. Ferguson,et al.  A single‐centre double‐blind trial of Trasylol therapy in primary acute pancreatitis , 1978, The British journal of surgery.

[25]  O. Zelder,et al.  Glucagon therapy in acute pancreatitis. Report of a double-blind trial. , 1978, Gut.

[26]  J. Condon,et al.  Glucagon therapy in acute pancreatitis , 1973, The British journal of surgery.

[27]  M. Kotb,et al.  Inhibition of TNFα improves survival in an experimental model of acute pancreatitis , 1996 .

[28]  J. Hermon-Taylor,et al.  Activation of human granulocyte type 1-prophospholipase A2. , 1996, Scandinavian journal of gastroenterology. Supplement.

[29]  M. Kotb,et al.  Inhibition of TNF alpha improves survival in an experimental model of acute pancreatitis. , 1996, The American surgeon.

[30]  J. Marshall,et al.  Multiple Organ Dysfunction Syndrome (MODS) , 1995 .

[31]  M. Kotb,et al.  Up-regulation of TNF alpha mRNA in the rat spleen following induction of acute pancreatitis. , 1995, The Journal of surgical research.

[32]  P. Malfertheiner,et al.  Gabexate mesilate in human acute pancreatitis. German Pancreatitis Study Group. , 1993, Gastroenterology.

[33]  P. Braquet,et al.  Effect of platelet-activating factor on monocyte activation and production of tumor necrosis factor. , 1989, International archives of allergy and applied immunology.